SPARK

SPARK Biopharma, founded by Dr. Seung Bum Park in 2016, focuses on the discovery and development of small molecule therapeutics aimed at modulating the tumor microenvironment (TME) in the field of immune oncology. The company collaborates with the CRI Center for Chemical Proteomics at Seoul National University and other scientific partners to advance its drug discovery programs. SPARK Biopharma leverages proprietary technology platforms such as pDOS, Seoul Fluor, and FITGE to identify and develop novel therapeutic agents. The business primarily serves the pharmaceutical and biotechnology sectors, targeting clients interested in innovative cancer treatments. SPARK Biopharma operates within the competitive landscape of oncology drug development, generating revenue through partnerships and potential licensing agreements for its clinical candidates. The company's business model is centered around research and development, with a focus on delivering effective and targeted cancer therapies. Keywords: small molecule, therapeutics, tumor microenvironment, immune oncology, drug discovery, chemical proteomics, pDOS, Seoul Fluor, FITGE, cancer treatment.